ElizabethMarySwisherMD

PubMed

• Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care
  Deborah J. Bowen, Catharine Wang, Allison M. Cole, Barbara M. Norquist, Sarah Knerr, Beth Devine, Brian H. Shirts, Kevin C. Cain, Heather M. Harris, Helen Ghirmai Hail...> ;Contemporary Clinical Trials. 2021 Feb 1
• Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma.
  Shogo Shigeta, Goldie Y. L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla G...> ;Molecular Cancer Therapeutics. 2021 Jan 1
• Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
  Talayeh S. Ghezelayagh, Kathryn P. Pennington, Barbara M. Norquist, Nithisha Khasnavis, Marc R. Radke, Mark R. Kilgore, Rochelle L. Garcia, Ming Lee, Ronit Katz, Kimbe...> ;Gynecologic Oncology. 2020 Dec 26
• BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
  Goldie Y. L. Lui, Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater, Robert L. Diaz, Rachele Rosati, Hallie A. Swan, Tan A. Ince, Thoma...> ;EBioMedicine. 2020 Oct 1
• The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study...
  Nicoletta Colombo, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Peter Dean, Johanne I. Weberpals, Andrew R Clamp, Giovanni Scambia, Alexandra Le...> ;Gynecologic Oncology. 2020 Oct 1
• Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years
  Arielle Shaeffer Weiss, Elizabeth M. Swisher, Kathryn P. Pennington, Marc R. Radke, Nithisha Khasnavis, Rochelle L. Garcia, Mark R. Kilgore, Ming K. Lee, Barbara M. No...> ;Gynecologic Oncology. 2020 Oct 1
• ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
  R.E. Miller, Alexandra Leary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Lederman...> ;Annals of Oncology. 2020 Sep 28
• 1 citations
  Comparative genomics of high grade neuroendocrine carcinoma of the cervix.
  R. Tyler Hillman, Robert J. Cardnell, Junya Fujimoto, Won-Chul Lee, Jianjun Zhang, Lauren Averett Byers, Preetha Ramalingam, Mario M. Leitao, Elizabeth M. Swisher, P. ...> ;PLOS ONE. 2020 Jun 16
• Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
  Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y., Schapiro, D., Zhou, Y., Graham, J. R., Dezube,...> ;Nature communications. 2020 May 20
• 2 citations
  BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
  Roshni Kalachand, Britta K. Stordal, Stephen F. Madden, Benjamin C. Chandler, Julie M. Cunningham, Ellen L. Goode, Ilary Ruscito, Elena Ioana Braicu, Jalid Sehouli, A ...> ;Journal of the National Cancer Institute. 2020 May 15
• 5 citations
  Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
  Erika J. Lampert, Alexandra S Zimmer, Michelle R Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon,...> ;Clinical Cancer Research. 2020 May 12
• Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-c...
  Ledermann, J. A., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., Leary, A., Holloway, R. W., ...> ;The Lancet. Oncology. 2020 May 4
• 1 citations
  Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institu...
  Shannon K. Rush, Elizabeth M. Swisher, Rochelle L. Garcia, Kathryn P. Pennington, Kathy J. Agnew, Mark R. Kilgore, Barbara M. Norquist> ;Gynecologic Oncology. 2020 May 1
• Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?
  Norquist, B. M., Swisher, E. M., Yung, R. L.> ;JNCI cancer spectrum. 2020 Apr 28
• 12 citations
  Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
  Anniina Färkkilä, Doga Can Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Y.L.E. Chen, Denis Schapiro, Yinghui...> ;Nature Communications. 2020 Mar 19
• Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
  Talayeh S. Ghezelayagh, Lauren E Stewart, Barbara M. Norquist, Deborah J. Bowen, Vivian Yu, Kathy J. Agnew, Kathryn P. Pennington, Elizabeth M. Swisher> ;Familial Cancer. 2020 Feb 24
• 2 citations
  Rare BRIP1 missense alleles confer risk for ovarian and breast cancer
  Cassandra L. Moyer, Jennifer Ivanovich, Jessica L. Gillespie, Rachel Doberstein, Marc R. Radke, Marcy E. Richardson, Scott H. Kaufmann, Elizabeth M. Swisher, Paul J. G...> ;Cancer Research. 2020 Feb 15
• 1 citations
  Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
  Yvette Drew, Rebecca Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, Noor R Md Haris, Elizabeth M. Swisher> ;Oncologist. 2020 Jan 1
• 3 citations
  Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
  Jorge, S., McFaddin, A. S., Doll, K. M., Pennington, K. P., Norquist, B. M., Bennett, R. L., Pritchard, C. C., Swisher, E. M.> ;Gynecologic oncology. 2019 Dec 31
• Characterization of splice-altering mutations in inherited predisposition to cancer.
  Casadei, S., Gulsuner, S., Shirts, B. H., Mandell, J. B., Kortbawi, H. M., Norquist, B. S., Swisher, E. M., Lee, M. K., Goldberg, Y., O'Connor, R., Tan, Z., Pritchard,...> ;Proceedings of the National Academy of Sciences of the United States of America. 2019 Dec 18
• Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
  Krimmel-Morrison, J. D., Ghezelayagh, T. S., Lian, S., Zhang, Y., Fredrickson, J., Nachmanson, D., Baker, K. T., Radke, M. R., Hun, E., Norquist, B. M., Emond, M. J., ...> ;Gynecologic oncology. 2019 Dec 17
• 5 citations
  BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
  Yifan Wang, Andrea J. Bernhardy, Joseph Nacson, John J. Krais, Yinfei Tan, Emmanuelle Nicolas, Marc R. Radke, Elizabeth Handorf, Alba Llop-Guevara, Judith Balmaña, Eli...> ;Nature Communications. 2019 Dec 11
• 3 citations
  Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
  Park, P. H., Yamamoto, T. M., Li, H., Alcivar, A. L., Xia, B., Wang, Y., Bernhardy, A. J., Turner, K. M., Kossenkov, A. V., Watson, Z. L., Behbakht, K., Casadei, S., S...> ;Molecular cancer therapeutics. 2019 Oct 3
• 84 citations
  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
  Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch,...> ;The New England Journal of Medicine. 2019 Sep 28
• Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline <i>BRCA</i> mutations.
  Jorge, S., Swisher, E. M., Norquist, B. M., Pennington, K. P., Gray, H. J., Urban, R. R., Garcia, R. L., Doll, K. M.> ;Gynecologic oncology reports. 2019 Aug 31
• Join now to see all